deprexis is an online programme for the treatment of depression, developed by GAIA AG in Hamburg. According to the vendor's website, it is evidence-based and supported by randomised controlled trials; these are the vendor's own claims. GAIA describes its focus as developing evidence-based, safe and accessible digital therapeutics, and the site presents deprexis as a current offering.
The vendor's site lists GAIA AG with an address in Hamburg and a US entity, GAIA America Inc., in New York. It does not name the operating entity for deprexis, does not state who owns GAIA AG, and does not say where patient data is hosted. The site shows certification logos, including ISO/IEC 27001, a TÜV Rheinland mark and a HIPAA assessment certificate, without describing their scope. For a European organisation, the German seat places the provider under EU data protection law, while hosting location and certification scope should be requested directly from the provider.